GILEAD SCIENCES, INC.

  • BCG Recommendation

Balfour Capital Group Researched GILEAD SCIENCES, INC. on November 23rd, 2023.

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Post Recommendation Price Trend Chart

Analysts Research

With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.

Argus Analysts on GILD

Argus Analysts Notes offers timely investment recommendations, insights.

Argus Analysts Notes

View

Argus Quantitive on GILD

Argus Quantitative analyzes energy, commodities, and finance with data analytics.

Argus Quantitive Report

View

2023 Q2 Earning Report

A Q2 report evaluates company financials for investors

GILD Report

View

Morgan Stanley ON GILD

Morgan Stanley researches Industries, offers insights to clients

Morgan Stanley Notes

View

Thomson Reuters on GILD

Thomson Reuters delivers global financial, legal, and business information to professionals.

Thomson Reuters

View
Balfour Capital Group wants to clarify that our recommendation to Buy GILEAD SCIENCES, INC. (GILD) is based on thorough research conducted by our dedicated teams. We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance. However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.

*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
error: Content is protected !!